Replimune Group, Inc. (REPL) Stock Price & Analysis
Replimune Group, Inc. (REPL) rose 3.01% to USD 9.24 as of June 10, 2026 at 00:58 UTC, according to Nexqual real-time market data.
REPL last closed at USD 8.97; the session ranged USD 8.42–9.31 on volume of 2,583,885 shares. Market capitalization is $762.97M, with a 52-week range of USD 1.5–13.24 (NMS). Source: Nexqual, June 10, 2026 at 00:58 UTC.
Key Statistics (as of June 10, 2026 at 00:58 UTC)
| Price | USD 9.24 |
|---|---|
| Change | ▲ 3.01% (up) |
| Previous Close | USD 8.97 |
| Open | USD 9.01 |
| Day Range | USD 8.42 – 9.31 |
| 52-Week Range | USD 1.5 – 13.24 |
| Volume | 2,583,885 shares |
| Market Cap | $762.97M |
| Exchange | NMS |
Technical Analysis (REPL)
Nexqual's technical model rates REPL "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.88 (overbought) |
| vs SMA50 | Above (USD 5.03) |
| MACD | 1.42 (positive) |
Analyst Ratings (REPL)
Wall Street analysts rate REPL "Hold" based on 6 analysts, with a mean price target of USD 4.67 (range USD 1–9), per Nexqual as of June 10, 2026 at 00:58 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 4.67 |
| High Target | USD 9 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 0 / 6 / 2 |
Earnings (REPL)
| Next Earnings Date | 2026-06-12 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $5.57M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.77 vs est -0.82 ▲ beat |
| 2025-09-30 | USD -0.9 vs est -0.79 ▼ miss |
| 2025-06-30 | USD -0.95 vs est -0.8 ▼ miss |
| 2025-03-31 | USD -0.82 vs est -0.69 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:58 UTC.
Financials & Fundamentals (REPL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -90.88% |
| Debt / Equity | 36.26 |
| Current Ratio | 5.6 |
| Total Cash | $269.14M |
| Total Debt | $76.35M |
| Free Cash Flow | $-172.75M |
Source: Nexqual, June 10, 2026 at 00:58 UTC.
Financial Health Score (REPL)
Nexqual rates Replimune Group, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $269M cash vs $76M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$278M |
| Efficiency | Critical — ROE -91%, ROA -43.2% |
Ownership (REPL)
| Insider Ownership | +2.60% |
|---|---|
| Institutional Ownership | +97.00% |
| Shares Outstanding | 82.57M |
| Float | 58.33M |
| Short % of Float | +56.33% |
Source: Nexqual, June 10, 2026 at 00:58 UTC.
Leadership (REPL)
Replimune Group, Inc. is led by Sushil Patel (age 54), CEO & Director, per Nexqual as of June 10, 2026 at 00:58 UTC.
| CEO & Director | Sushil Patel (age 54) |
|---|---|
| Chief Financial Officer | Emily Luisa Hill (age 45) |
| Executive Chairman | Philip Astley-Sparke F.S.A. (age 54) |
| Senior Vice President of Portfolio Strategy & Program Management | Nina Aragam |
| Senior Vice President of Quality Assurance | Carolyn Trott |
Major Backers & Investors (REPL)
Notable institutional backers of Replimune Group, Inc. include Baker Bros. Advisors, LP, Price (T.Rowe) Associates Inc, RTW Investments LP, according to Nexqual as of June 10, 2026 at 00:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 13.38% |
| Price (T.Rowe) Associates Inc | 11.09% |
| RTW Investments LP | 8.91% |
| T. Rowe Price | 6.59% |
| Suvretta Capital Management, LLC | 5.11% |
| FCPM III Services B.V. | 3.4% |
| Shaw D.E. & Co., Inc. | 2.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.58% |
| State Street | 7.48% |
| Vanguard Group | 6.61% |
Source: Nexqual, June 10, 2026 at 00:58 UTC.
From Replimune Group, Inc.'s Latest SEC 10-K Filing (filed 2025-05-22)
Key Strengths & Strategy (as disclosed to the SEC)
- Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
- The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
- Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
- The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:58 UTC. This page is informational and not investment advice.